Abstract:An enzymatic method has been successfully established enabling the generation of partially base-modified RNA (previously named RZA) constructs, in which all G residues were replaced by isomorphic fluorescent thienoguanosine ( th G) analogs, as well as fully modified RZA featuring th G, 5-bromocytosine, 7-deazaadenine and 5-chlorouracil. The transcriptional efficiency of emissive fully modified RZA was found to benefit from the use of various T7 RNA polymerase variants. Moreover, d th G could be incorporated into PCR products by Taq DNA polymerase together with the other three base-modified nucleotides. Notably, the obtained RNA products containing th G as well as th G together with 5-bromocytosine could function as effectively as natural sgRNAs in an in vitro CRISPR-Cas9 cleavage assay. N 1 -Methylpseudouridine was also demonstrated to be a faithful non-canonical substitute of uridine to direct Cas9 nuclease cleavage when incorporated in sgRNA. The Cas9 inactivation by 7-deazapurines indicated the importance of the 7-nitrogen atom of purines in both sgRNA and PAM site for achieving efficient Cas9 cleavage. Additional aspects of this study are discussed in relation to the significance of sgRNA–protein and PAM–-protein interactions that were not highlighted by the Cas9–sgRNA–DNA complex crystal structure. These findings could expand the impact and therapeutic value of CRISPR-Cas9 and other RNA-based technologies. Nucleobase modifications enzymatically incorporated into the CRISPR-Cas9 system revealed the tolerance of Cas9 to m1Ψ- and fluorescent th G-modified sgRNA and requirements for PAM recognition. With the advent of CRISPR-Cas9 gene editing, we now have to hand a simple two-component system amendable to silencing and knock-in editing effectively any gene. Yet we must not forget that the implications of immunotoxicity along with the poor stability and specificity of canonical nucleic acids hold enormous challenges for in vivo applications, especially in gene therapy. Our study endorses the feasibility of the enzymatic approach to incorporate nucleobase modifications into the CRISPR-Cas9 system unveiling the tolerance of Cas9 to N 1 -methylpseudouridine (m1Ψ)- and emissive thienoguanosine ( th G)-modified sgRNA as well as thus far uncharted structural requirements for ensuring proper PAM recognition.

Effect of the Phosphoryl Guanidine Modification in Chimeric DNA-RNA crRNAs on the Activity of the CRISPR-Cas9 System In Vitro

CRISPR-Cas9 recognition of enzymatically synthesized base-modified nucleic acids

Chemical Modification and Transformation Strategies of Guide RNAs in CRISPR‐Cas9 Gene Editing Systems

Extensive CRISPR RNA modification reveals chemical compatibility and structure-activity relationships for Cas9 biochemical activity

Screening DNA Aptamers That Control the DNA Cleavage, Homology-Directed Repair, and Transcriptional Regulation of the CRISPR-(d)Cas9 System.

Partial DNA-guided Cas9 enables genome editing with reduced off-target activity

A platform to deliver single and bi-specific Cas9/guide RNA to perturb genes in vitro and in vivo

The impact of nucleosome structure on CRISPR/Cas9 fidelity

Chimeric CRISPR-CasX enzymes and guide RNAs for improved genome editing activity

Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases

Regulation of the CRISPR-Cas12a System by Methylation and Demethylation of Guide RNA.

Regulation of CRISPR-Cas12a system by methylation and demethylation of Guide RNA

Synthetic Circular gRNA Mediated Biological Function of CRISPR-(d)Cas9 System

Computationally Engineered CRISPR-SpyCas9 High-Fidelity Variants with Improved Specificity and Reduced Non-specific DNA Damage

Deleting Specific Residues From the HNH Linkers Creates A CRISPR-SpCas9 Variant With High Fidelity and Efficiency

Disabling Cas9 by an anti-CRISPR DNA mimic

An Efficient Expression and Purification Protocol for SpCas9 Nuclease and Evaluation of Different Delivery Methods of Ribonucleoprotein

Chimeric CRISPR guides enhance Cas9 target specificity

Optimizing a CRISPR-Cas13d Gene Circuit for Tunable Target RNA Downregulation with Minimal Collateral RNA Cutting

CRISPR/Cas9 Technology: Challenges and drawbacks

Reducing CRISPR-Cas9 off-target effects by optically controlled chemical modifications of guide RNA